Medicare Reform to Flatten Gilead's Booming HIV Sales
A change in Medicare policy is expected to flatten revenue from Gilead Science's HIV products, one of its most profitable segments.
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...